GlassScriptPhysician profile
Sakina E Abowath
NPI 1326287525
$7,048.29
in general payments reported to CMS, 2019-2025
24 companies · $967 in 2025
The $967 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $943 · 2022: $1,761 · 2023: $1,667 · 2024: $1,711 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,086 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,085.99 |
| Education | $258.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,720.14 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,698.16 | 2021-2025 | |
| Incyte Corporation | $1,038.15 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $565.84 | 2021-2025 | |
| Leo Pharma INC. | $459.57 | 2021-2025 | Adbry |
| Pfizer INC. | $407.59 | 2021-2025 | |
| Dermavant Sciences, INC. | $205.45 | 2023-2024 | Vtama |
| Amgen INC. | $192.62 | 2021-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $114.81 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $106.68 | 2022 | |
| Abbvie INC. | $87.40 | 2025 | |
| Sun Pharmaceutical Industries INC. | $57.74 | 2022-2023 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $52.88 | 2023 | |
| Verrica Pharmaceuticals INC. | $48.18 | 2024 | Ycanth |
| Dermira, INC. | $47.72 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.16 | 2022-2023 | Spevigo |
| Phadia US INC. | $35.18 | 2021 | |
| Almirall LLC | $29.75 | 2022 | |
| Galderma Laboratories, L.P. | $27.60 | 2024 | |
| Organon LLC | $26.78 | 2025 | Vtama |
| Regeneron Pharmaceuticals, INC. | $25.90 | 2023 | Dupixent |
| Lnhc, INC | $23.12 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.76 | 2021 | |
| Epi Health, LLC | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakina Abowath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.